Recognizing AML with eosinophilia due to PDGFRA and PDGFRΒ rearrangement is important, because the aberrant tyrosine kinase activity can make the disease responsive to tyrosine kinase inhibitors such as imatinib. This evidence concerns the gene PDGFRA and Increased total eosinophil count.